A nuanced perspective?

In their editorial, White & Sashidharan point to the putatively good outcomes in schizophrenia in low- and middle-income countries (LMIC), ‘where populations may not have access to medication-based treatments.’ This evidence is offered as a caution against scaling up biomedical interventions in LMIC. White & Sashidharan then make a plea for ‘a more balanced exchange of knowledge . . . between high-income countries and LMIC. However, in only citing evidence from the World Health Organization (WHO) studies of schizophrenia, and neglecting a wealth of evidence from studies in LMIC, they do not heed their own advice for a greater exchange of knowledge. In fact, research conducted by investigators in India, Ethiopia and China suggests that the provision of biomedical treatment does, in fact, improve outcomes in persons with schizophrenia. Furthermore, by only citing the WHO studies, White & Sashidharan do not, despite the title of their editorial, offer a nuanced perspective on this question. When considering the evidence from the long-term research on schizophrenia outcomes in LMIC, there is no doubt that the picture is one of heterogeneity and complexity. Thus, by only citing the WHO studies, White & Sashidharan fail to acknowledge the work of a large number of psychiatric researchers from LMIC.

It is difficult, if not impossible, to defend the statement, ‘better outcomes for complex mental health difficulties in LMIC . . . may be a consequence of the multiplicity of treatment/healing options available in LMIC compared with high-income countries’. First, I would hazard to guess that there are as many, if not more, options for treatment and healing in London, New York, Paris and Sydney than there are in New Delhi, Beijing, Lagos and Rio de Janeiro. For example, in much of Indonesia the options for care are so limited or nonexistent that families often resort to pasung, the practice of chaining, shackling or confining psychotic individuals, in an attempt to protect those individuals from harming themselves or others. Second, having a multiplicity of options does not necessarily result in better outcomes. It can also lead to a continuous sampling of ineffective cures offered by charlatans.

I do not mean these comments to be taken as a tacit endorsement of the indiscriminate use of psychotropic medication. Antidepressants and antipsychotics are less effective than desired and both are associated with troubling side-effects. Rather, these comments are offered in the hope that White & Sashidharan, as well as others, will be prompted to provide a truly nuanced perspective on what is needed to improve the lives of individuals who experience severe mental illness, wherever they reside.

Authors’ reply: We feel it is important to respond to several points that Dr Cohen made in his letter. In our editorial, we did not propose that psychotropic medications should not be part of the treatment options for people with mental health difficulties living in LMIC. Instead, we questioned whether these medications should necessarily be the front-line treatment, and highlighted concerns about their long-term use. We cited the most comprehensive studies conducted to date to highlight that outcomes for serious mental health difficulties in high-income countries (HIC) are not superior to those in LMIC. The suggestion that outcomes were better in countries where populations may not have access to antipsychotic medications is supported by the WHO finding that ‘Patients in developing countries experienced significantly longer periods of unimpaired functioning in the community, although only 16% of them were on continuous anti-psychotic medication (compared with 61% in the developed countries).’

A recent meta-analysis of studies that have investigated antipsychotic medication for maintenance treatment of schizophrenia found that antipsychotic medications were superior to placebo in preventing relapse, and that the medication-placebo difference was smaller in longer, compared with shorter, trials. Various methodological issues were noted with the studies. More rigorously controlled long-term trials are required in both HIC and LMIC to investigate the impact of antipsychotic medications on recovery (incorporating a focus on social participation and citizenship) from serious mental health difficulties. Consistent with a previous British Journal of Psychiatry editorial and the Kampala Declaration, we believe that it is important for people to have the right to freely choose whether they take psychotropic medication on the basis of balanced information about the potential long-term benefits and costs of these treatments.

Dr Cohen casts doubt on the suggestion that the multiplicity of treatment/healing options for mental health difficulties available in LMIC may be associated with better mental health outcomes there. He points out that a range of potential treatment options is also available in HIC. Halliburton has spoken directly to this point, by commenting that in ‘developing country sites in the WHO studies, multiple medical systems exist within the mainstream and are often considered mutually compatible, whereas in most developed sites allopathic medicine is more hegemonic and “alternative” systems are more marginal.’ Indeed, it has been suggested that, over the past 200 years, complementary and alternative systems have contended with orchestrated resistance from biomedicine.

Whether non-biomedical interventions provided in HIC or LMIC are safe and efficacious is a matter for careful consideration and empirical investigation. Recent evidence from Ghana has indicated that human rights abuses can occur not only in non-biomedical settings (such as prayer camps), but in psychiatric hospitals as well. It is estimated that two-thirds of the global population rely on traditional forms of medicine used concurrently with, or as alternatives to, biomedicine. We would suggest that dismissing out of hand the contribution of non-biomedical practitioners as the work of ‘charlatans’ potentially risks disenfranchising people from important sources of support.

7 Jablensky A, Sartorius N. What did the WHO studies really find? Schizophr Bull 2008; 34: 253–5.
Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. *BJP*, 204, 98–107. The authors regretfully report that errors were made in some of the data analyses in the above review, as follows.

1. **A unit-of-analysis error was made through combining both treatment and control conditions when studies included two or more comparator groups or multiple time points.**

2. **A withdrawal study by Habraken *et al.* (1997) was inappropriately included in the meta-analysis.** This should not have been included as the authors used a control condition in which participants were required to keep using benzodiazepines rather than stop using them. All other withdrawal studies used comparator conditions in which participants were required to stop using these drugs with an active or non-active control intervention.

3. **There were a few small errors in the calculation of the odds ratio and/or standard error for Pitt *et al.* (2007) and Avorn *et al.* (1992).**

Consequently, all raw data have now been re-checked, all errors corrected and all analyses re-calculated. After re-analysis, the pattern of results and conclusions remain unchanged from those originally reported in the review, with the minor exception of the following.

1. **There is no longer any evidence of heterogeneity in effect sizes for withdrawal with psychotherapy at 0.5–3 months.** Thus, the conclusion that this type of intervention may not always be effective (*v.* control conditions) in individual settings no longer stands.

2. **Although type of intervention just failed to reach significance in the univariate meta-regression of prescribing interventions, it remained significant in the subgroup analysis.** Consequently, the conclusion that the odds of not using benzodiazepines were higher for multifaceted prescribing interventions than for single-faceted ones remains unchanged.

Annotations to the published review and supplementary tables detailing these changes are presented as a data supplement to this correction.

**doi:** 10.1192/bjp.205.4.330

---

**Correspondence**


---

**Correction**

Ross White, Senior Lecturer, Director of MSc Global Mental Health Programme, Institute of Health and Wellbeing, University of Glasgow. Email: ross.white@glasgow.ac.uk; S. P. Sashidharan, PhD, Centre for Population Health Sciences, University of Glasgow.

doi: 10.1192/bjp.205.4.329a
A nuanced perspective?
Alex Cohen
Access the most recent version at DOI: 10.1192/bjp.205.4.329

References
This article cites 3 articles, 2 of which you can access for free at:
http://bjp.rcpsych.org/content/205/4/329.1#BIBL

Reprints/permissions
To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at
/letters/submit/bjprcpsych;205/4/329

Downloaded from
http://bjp.rcpsych.org/ on April 3, 2017
Published by The Royal College of Psychiatrists

To subscribe to The British Journal of Psychiatry go to:
http://bjp.rcpsych.org/site/subscriptions/